Sádi-Arabía - enska - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

amdipharma, ireland - imipramine hydrochloride - tablet - 25 mg

Írland - enska - HPRA (Health Products Regulatory Authority)

novartis pharmaceuticals uk ltd - imipramine hydrochloride - tablets - 25 mg milligram

Írland - enska - HPRA (Health Products Regulatory Authority)

novartis pharmaceuticals uk ltd - imipramine hydrochloride - tablets - 25 mg milligram

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - imipramine hydrochloride 10mg - coated tablet - 10 mg - active: imipramine hydrochloride 10mg excipient: colloidal silicon dioxide copovidone glycerol hypromellose 15028 dispersed red lactose monohydrate macrogol 8000 magnesium stearate maize starch microcrystalline cellulose povidone purified talc     purified water stearic acid sucrose titanium dioxide - all forms of depression, including endogenous, organic and psychogenic forms, and depression associated with personality disorders or chronic alcoholism.

Bangladess - enska - DGDA (Directorate General of Drug Administration)

novartis (bangladesh) ltd. - imipramine hydrochloride - tablet - 25 mg

Egyptaland - enska - EDA (Egyptian Drug Authority)

novartis pharma-switzerland - coated tablet - 25 mg

Kanada - enska - Health Canada

novartis pharmaceuticals canada inc - imipramine hydrochloride - tablet - 50mg - imipramine hydrochloride 50mg - tricyclics and other norepinephrine-reuptake inhibitors

Kanada - enska - Health Canada

novartis pharmaceuticals canada inc - imipramine hydrochloride - tablet - 75mg - imipramine hydrochloride 75mg - tricyclics and other norepinephrine-reuptake inhibitors

Kanada - enska - Health Canada

sanofi-aventis canada inc - desipramine hydrochloride - tablet - 25mg - desipramine hydrochloride 25mg - tricyclics and other norepinephrine-reuptake inhibitors

Bandaríkin - enska - NLM (National Library of Medicine)

specgx llc - imipramine hydrochloride (unii: bke5q1j60u) (imipramine - unii:ogg85sx4e4) - imipramine hydrochloride 10 mg - depression – for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than other depressive states. one to three weeks of treatment may be needed before optimal therapeutic effects are evident. childhood enuresis – may be useful as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older, after possible organic causes have been excluded by appropriate tests. in patients having daytime symptoms of frequency and urgency, examination should include voiding cystourethrography and cystoscopy, as necessary. the effectiveness of treatment may decrease with continued drug administration. the concomitant use of monoamine oxidase inhibiting compounds is contraindicated. hyperpyretic crises or severe convulsive seizures may occur in patients receiving such combinations. the potentiation of adverse effects can be serious, or even fatal. when it is desired to substitute tofranil in patients receiving a monoamine oxidase inhibitor, as long an interval sho